{"prompt": "['Novartis', 'Confidential', 'Page 12', 'Amended Protocol Version v02/Clean', 'Protocol No. CQVM149B2306', 'Protocol summary', 'Protocol number', 'CQVM149B2306', 'Full Title', 'A multicenter, partially-blinded, randomized, 24-week, parallel-', 'group, non-inferiority, open-label active controlled study to compare', 'the efficacy and safety of QVM149 with a free triple combination of', 'salmeterol/fluticasone + tiotropium in patients with uncontrolled', 'asthma', 'Brief title', 'Efficacy study of QVM149 in uncontrolled asthma patients', 'Sponsor and Clinical', 'Novartis', 'Phase', '3b', 'Investigation type', 'Drug', 'Study type', 'Interventional', 'Purpose and rationale', 'The purpose of this trial is to demonstrate that the efficacy of two', 'strengths of the fixed-dose combination product QVM149', '(IND/GLY/MF150/50/80 g and IND/GLY/MF 150/50/160 g) is', 'non-inferior to the efficacy of the free combination of salmeterol', 'xinafoate/fluticasone propionate 50/500 g + tiotropium 5 g in', 'uncontrolled asthmatics.', 'Primary Objective(s)', 'To demonstrate non-inferiority of either QVM149 high-dose or', 'QVM149 medium-dose to comparator salmeterol / fluticasone +', 'tiotropium after 24 weeks of treatment in terms of Asthma Quality of', 'Life Questionnaire.', 'Secondary Objectives', 'To evaluate efficacy of QVM149 high-dose and QVM149', 'medium-dose compared to salmeterol/ fluticasone + tiotropium in', 'terms of Trough FEV1 after 24 weeks of treatment.', 'To evaluate efficacy of QVM149 high-dose and QVM149', 'medium-dose compared to salmeterol/ fluticasone + tiotropium in', 'terms of Asthma Quality of Life Questionnaire over 24 weeks of', 'treatment.', 'To evaluate efficacy of QVM149 high-dose and QVM149', 'medium-dose compared to salmeterol/ fluticasone + tiotropium in', 'terms of Asthma Control Questionnaire over 24 weeks of', 'treatment.', 'To evaluate efficacy of QVM149 high-dose and QVM149', 'medium-dose compared to salmeterol/ fluticasone + tiotropium in', 'terms of lung function over 24 weeks of treatment.', 'Study design', 'This study uses a multicenter, partially-blinded, randomized, 24-']['Novartis', 'Confidential', 'Page 13', 'Amended Protocol Version v02/Clean', 'Protocol No. CQVM149B2306', 'week, parallel-group, non-inferiority, open-label active controlled', 'design.', 'The study will consist of a screening period of up to 1-week, run-in', 'period of 2-weeks, randomized treatment period of 24-weeks, and a', 'follow-up of period of 1-week.', 'Population', 'The study population will consist of approximately 1251 male and', 'female patients with uncontrolled asthma aged 18 and above.', 'Key Inclusion criteria', 'Written informed consent must be obtained before any study-', 'related assessment is performed; only fully legally competent', 'patients can be included.', 'Male and female adult patient > 18 years old.', 'Patients with a diagnosis of asthma for a period of at least 6', 'months prior to Visit 1 with current asthma severity > step 4', '(GINA 2017).', 'Patients who have used ICS/LABA combinations for asthma for', 'at least 3 months and at stable medium or high dose of', 'ICS/LABA for at least 1 month prior to Visit 1.', 'Patients must be symptomatic at screening despite treatment with', 'medium or high stable doses of ICS/LABA as defined by ACQ-7', 'score > 1.5 at visits 101 and 201 (randomization visit).', 'Patients with history of at least one severe asthma exacerbation', '(see Section 6.4.5) which required medical care from a physician,', 'Emergency Room (ER) visit (or local equivalent structure) or', 'hospitalization in the 12 months prior to Visit 1 and required', 'systemic corticosteroids (SCS) treatment for at least 3 days', 'including physician guided self-management treatment with oral', 'corticosteroids (OCS) as part of written asthma action plan.', 'Pre-bronchodilator FEV1 of < 85% of the predicted normal', 'value for the patient after withholding bronchodilators prior to', 'spirometry at both Visit 101 and Visit 201.', 'Patients who demonstrate an increase in FEV1 of > 12% and 200', 'mL.', 'Key Exclusion criteria', 'Patients who have a smoking history of greater than 20 pack', 'years.', 'Patients diagnosed with Chronic Obstructive Pulmonary Disease', '(COPD).', 'Patients who have had an asthma attack/exacerbation requiring', 'systemic steroids or hospitalization or emergency room visit', 'within 6 weeks of Visit 1 (Screening).', 'Patients treated with a LAMA for asthma within 3 months prior', 'to Visit 1.', 'Patients who have had a respiratory tract infection or clinical']\n\n###\n\n", "completion": "END"}